Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 16, Issue 2, Pages 209-223Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2012.658370
Keywords
fatty acids; IL-6; NF-kappa B; PPAR beta/delta; STAT-3
Categories
Funding
- Ministerio de Ciencia e Innovacion of Spain [SAF2009-06939]
Ask authors/readers for more resources
Introduction: The nuclear receptors Peroxisome Proliferator-Activated Receptors (PPAR)alpha and PPAR gamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively. Evidence is now emerging that the PPAR beta/delta isotype is a potential pharmacological target for the treatment of insulin resistance and type 2 diabetes mellitus. Areas covered: In this review, the capacity of PPAR beta/delta to prevent the development of insulin resistance and type 2 diabetes mellitus is discussed. Special emphasis is placed on preclinical studies and the molecular mechanisms responsible for its actions in the main cell types involved in these pathologies: adipocytes, beta-cells, skeletal muscle cells and hepatocytes. Expert opinion: While several concerns remain for the development of PPAR beta/delta agonists, these drugs have demonstrated their efficacy in the treatment of insulin resistance and type 2 diabetes mellitus in preclinical studies, as well as in a few short clinical studies in humans. Although this data is promising, additional studies must be performed to confirm the efficacy and safety of these drugs in the treatment of type 2 diabetes mellitus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available